[pronut-hiv] HIV/AIDS HAART: HIV/AIDS patients on efavirenz therapy have high-density lipoprotein cholesterol increase

["ProNut-HIV" <pronut-hiv@healthnet.org>]

HIV/AIDS HAART: HIV/AIDS patients on efavirenz therapy have high-density lipoprotein cholesterol increase

AIDSWEEKLY Plus; Monday, July 10, 2006
Staff Medical Writers


--------------------------------------------------------------------------
NewsRx -- High-density lipoprotein cholesterol is increased in a dose-dependent manner in HIV/AIDS patients on efavirenz therapy. 
In a recent article published in the British Journal of Clinical Pharmacology, scientists in Portugal conducted a study to "investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG)."

"Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months."

"In patients with baseline HDL-C <40 mg/dL-1," wrote S.A. Pereira and colleagues at the New University of Lisbon, "an increase in HDL-C from 31±1 mg/dL-1 to 44±2 mg/dL-1 (95% confidence interval 5.9, 21.9, p<0.01) was observed and remained throughout the follow-up period."

"Median efavirenz plasma concentration was 1.98 mg/L-1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found," reported the authors.

Researchers concluded, "There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients."

Pereira and colleagues published their study in British Journal of Clinical Pharmacology (Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. Br J Clin Pharmacol. 2006 May;61(5):601-4).

Additional information can be obtained by contacting E.C. Monteiro, New University of Lisbon, Faculty Med Science, Dept. Pharmacology, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.

The publisher of the British Journal of Clinical Pharmacology can be contacted at: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Lisbon, Portugal, HIV/AIDS, Efavirenz, High-Density Lipoprotein Cholesterol, Plasma Concentrations, Long-Term Effect.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Pereira SA, Branco T, Corte-Real RM, et al., "Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients", Br J Clin Pharmacol. 2006 May;61(5):601-4.

PubMED Related articles Search

2006-07-10
AW060704


---------------------------------------------------------------------------

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net